Frontiers in Aging Neuroscience · Nov 19, 2026
MASLD and Risk of Alzheimer's Disease and Vascular Dementia: A Systematic Review and Meta-Analysis of Cohort Studies
By Yiyi Fu, Wanjia Zhang, Weiqing Yang et al.
Background: Previous epidemiological studies investigating the association between steatotic liver disease and dementia have yielded contradictory findings. Furthermore, the cognitive impact of the newly defined metabolic dysfunction-associated steatotic liver disease(MASLD) and its MetALD subtype remains unclear. This study evaluates their longitudinal associations with dementia risk. Methods: A systematic review and meta-analysis were conducted following PRISMA 2020 guidelines. We systematically searched four electronic databases(PubMed, Web of Science, Cochrane Library, and Embase) up to Oct 25, 2026, for cohort studies reporting hazard ratios(HRs) for dementia in individuals with MASLD or MetALD. Pooled HRs were estimated using random-effects models. Results: Ten studies comprising 11 independent cohorts and involving over four million participants were included. MASLD was associated with an increased risk of AD (HR 1.12, 95% CI 1.06–1.19; I² = 68%), although this association was sensitive to the exclusion of individual studies. No significant associations were observed between MASLD and all-cause dementia (HR 1.04, 95% CI 0.96–1.11; I² = 91%) or VaD (HR 1.14, 95% CI 0.97–1.34; I² = 80%). However, excluding Labenz et al. yielded a significant association with VaD in an exploratory sensitivity analysis (HR 1.23, 95% CI 1.16–1.32; I² = 0%). MetALD was associated with an increased risk of VaD (HR 1.28, 95% CI 1.13–1.46; I² = 0%), although this finding was based on only two cohorts. No significant associations were observed between MetALD and all-cause dementia or AD. Conclusion: This meta-analysis provides preliminary evidence of potential associations between MASLD, MetALD, and specific dementia subtypes. However, substantial heterogeneity and limited evidence warrant cautious interpretation. Rather than indicating an independent causal relationship, these associations suggest that MASLD may serve as a hepatic manifestation and phenotypic marker of cumulative systemic cardiometabolic and genetic burdens linked to long-term neurodegenerative outcomes. Further large-scale prospective studies using advanced imaging are needed to clarify these associations.